STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Overview

Inspira Technologies Oxy BHN Ltd (IINN) is a specialty medical device company committed to transforming the landscape of respiratory care. With a focus on life support and respiratory treatment, the company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART) that provides a non-invasive alternative to traditional mechanical ventilation. The technology is designed to elevate oxygen saturation and reduce carbon dioxide levels in patients, addressing a critical need in the management of acute respiratory failure.

Core Technology and Innovation

The hallmark of Inspira Technologies is its pioneering approach to respiratory support. Its INSPIRA ART system employs advanced principles of extracorporeal oxygenation, substituting the direct mechanical intervention of traditional ventilators with a sophisticated intravascular apparatus. This device promises to stabilize oxygen levels rapidly without the complications that are often associated with mechanical ventilation, thereby offering patients the possibility of remaining awake during treatment.

Complementing the INSPIRA ART is the company’s innovative HYLA blood sensor technology. This AI-powered continuous monitoring system provides real-time data on a patient’s blood oxygenation and carbon dioxide levels, allowing healthcare professionals immediate access to critical parameters. The integration of HYLA enhances the utility of the INSPIRA ART, offering continuous feedback and contributing to a more informed clinical decision-making process.

Market Significance and Competitive Position

Inspira Technologies operates in a competitive yet rapidly evolving segment of the medical devices market. The problems associated with invasive mechanical ventilation, such as high treatment costs, complications, and a heavy burden on ICU resources, position the company’s offerings as potentially disruptive in a market that handles millions of cases of acute respiratory failure annually. By addressing both the mechanical and monitoring aspects of respiratory support through its dual technologies, the company is carving out a unique position that resonates with healthcare providers who seek safer, more efficient, and patient-centric solutions.

Regulatory Achievements and Clinical Insights

The company has achieved significant regulatory milestones, obtaining clearance for its INSPIRA ART systems in key procedures such as Cardiopulmonary Bypass. These clearances underscore the robustness and safety of its design. Additionally, the clinical evaluations of its HYLA blood sensor technology at internationally recognized medical institutions demonstrate the company’s commitment to aligning innovation with established clinical protocols and standards.

Product Portfolio and Operational Excellence

Beyond its flagship INSPIRA ART system and the supporting HYLA sensor, Inspira Technologies is actively developing a robust pipeline of products aimed at addressing various facets of respiratory support and blood monitoring. The company’s research, development, manufacturing, and marketing operations are tailored to meet the rigorous demands of modern critical care, emphasizing ease of use, rapid response, and integration with existing hospital systems.

Strategic Collaborations and Global Reach

Recognizing the global need for improved respiratory care, Inspira Technologies has engaged in strategic collaborations with leading hospitals and distributors across multiple regions including North America, Europe, and Asia Pacific. These partnerships not only validate the technological merits of the company’s products but also help penetrate diverse healthcare markets that continue to rely heavily on traditional ventilation methods.

Commitment to Quality and Clinical Impact

The company’s approach blends robust technological innovation with a keen understanding of clinical challenges. By focusing on continuous innovation through rigorous trial evaluations, adherence to regulatory standards, and integration of AI-powered analytics, Inspira Technologies is dedicated to enhancing patient outcomes in critical care settings while alleviating operational burdens on healthcare providers.

Conclusion

Inspira Technologies Oxy BHN Ltd represents a thoughtful blend of technical innovation and clinical pragmatism. It stands out for its effort to revolutionize respiratory support through cutting-edge non-invasive technologies that offer an alternative to conventional mechanical ventilation. With a comprehensive business model centered on enhancing both patient care and operational efficiency in critical care environments, the company is well-positioned in its sector as healthcare institutions increasingly seek solutions that combine safety, rapid responsiveness, and sustained reliability.

Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) announced an exclusive distribution agreement with Glo-Med Networks for their respiratory support system across six U.S. states, including Texas and Florida. This agreement, with an initial term of seven years, aims to deploy a minimum of 2,121 ART systems and 131,413 disposable units, subject to regulatory approvals. The company projects a potential $174 million market opportunity in Europe, building on previous agreements. Inspira aims to enhance its U.S. market presence and improve respiratory treatment for patients in need.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.52%
Tags
none
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) has announced that a key component of its ART and ECLS systems is now listed on the FDA Class I 510(k) exempt list. This component aims to mitigate complications from jugular vein cannula movement during patient transport and is expected to enhance safety for awake ECMO patients during mobilization. Although the ART system is designed for cost-effective respiratory support, it has not yet been tested on humans nor received approval from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced the appointment of Professor Daniel Brodie to its Scientific Advisory Board. Prof. Brodie, known for his expertise in critical care and extracorporeal life support, leads the Adult ECMO Program at Columbia University/New York-Presbyterian Hospital. His appointment follows other notable additions to the advisory board, enhancing the company's leadership in respiratory support technology. Inspira is developing the ART device, an innovative system aimed at improving oxygenation in respiratory patients, although it has not yet received FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
management
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has signed an exclusive distribution agreement with Innovimed for the ART device in Poland, Czech Republic, and Slovakia. The agreement, with an initial term of 7 years, includes a commitment to purchase a minimum of 1,552 ART devices and 59,040 disposable units. This follows a prior agreement with WAAS Group for potential revenues of $66 million in Spain and Portugal. The ART device aims to reduce the need for invasive mechanical ventilation for respiratory failure patients, pending regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
84.01%
Tags
none
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has filed a Patent Cooperation Treaty application for its ART device, an early-stage extracorporeal respiratory support system. Designed to assist patients while awake, the ART aims to reduce the need for invasive mechanical ventilation. This innovative system enriches blood oxygen levels rapidly, utilizing a low-flow approach that minimizes complications associated with traditional methods. The ART is poised for deployment both in and outside ICU settings, contributing to cost-effective respiratory care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) announced the addition of Professor Eddy Fan to its Scientific Advisory Board. Prof. Fan, a critical care specialist from the University of Toronto, aims to enhance the development of Inspira's innovative ART device, designed for respiratory support in patients with acute conditions. This collaboration is expected to improve the clinical applications of the ART device, although it remains untested in humans and lacks regulatory approvals. CEO Dagi Ben-Noon emphasized the significance of Prof. Fan's expertise in advancing hybrid respiratory support solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
management
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) reported its Q3 2021 financial results, showcasing significant progress following an exclusive agreement with WAAS Group for over 1,000 ART systems deployment in Spain and Portugal. The Company raised capital after most IPO warrants were exercised at $5.50 per share. R&D expenses decreased to $1.7 million while net loss increased to $6 million. Notably, Q3 net profit surged to $2.2 million. Cash reserves rose to $17 million, significantly up from $496,000 at year-end 2020, reflecting positive IPO proceeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.54%
Tags
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced the appointment of Dr. Stephane Ledot to its Scientific Advisory Board. Dr. Ledot, an expert in critical care and anesthesia, brings extensive experience to the role, having previously served as director of the ECMO service at Royal Brompton Hospital. His expertise is expected to enhance the company’s efforts in developing the ART device, an innovative extracorporeal respiratory support system. The device aims to support patients with acute respiratory failure without the need for mechanical ventilation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
management
-
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that Co-Founder and CFO Joe Hayon will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15 at 2:30 PM EST. One-on-one meetings are available for attendees. A replay of the presentation will be accessible on Inspira's investor relations page post-event. Inspira Technologies is developing the ART device, an innovative respiratory support system designed to act as an 'Artificial Lung' for patients, though it has yet to be tested in humans and is not FDA-approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has filed a Patent Cooperation Treaty application for its innovative dual lumen cannula designed to enhance respiratory care. This novel device aims to improve patient outcomes by preventing complications like air embolisms, bleeding, and infection. The dual lumen cannula allows for bedside insertion into large blood vessels, quickly rebalance oxygen saturation while reducing human error. CEO Dagi Ben-Noon highlighted the goal to offer cost-effective support for patients with acute respiratory failure, though the product is still in development and not FDA approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none

FAQ

What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?

The current stock price of Inspira Technologies Oxy Bhn (IINN) is $0.6414 as of April 1, 2025.

What is the market cap of Inspira Technologies Oxy Bhn (IINN)?

The market cap of Inspira Technologies Oxy Bhn (IINN) is approximately 17.0M.

What is the core business of Inspira Technologies Oxy BHN Ltd?

Inspira Technologies focuses on developing innovative respiratory support and life support technologies that serve as alternatives to invasive mechanical ventilation.

How does the INSPIRA ART system differ from traditional mechanical ventilators?

The INSPIRA ART system is designed to enhance oxygen levels and remove carbon dioxide using an intravascular approach, potentially reducing complications and allowing patients to remain awake during treatment.

What role does the HYLA blood sensor technology play in Inspira's product portfolio?

The HYLA blood sensor provides real-time, continuous monitoring of blood parameters, enabling immediate clinical feedback and supporting informed decisions during respiratory treatment.

Which market segments does Inspira Technologies serve?

The company targets the respiratory care and life support markets globally, with applications in intensive care units, operating rooms, and other critical care settings.

What regulatory achievements has Inspira Technologies accomplished?

Inspira Technologies has obtained key regulatory clearances, such as FDA 510(k) clearance for its INSPIRA ART systems in procedures like Cardiopulmonary Bypass, underscoring its commitment to safety and clinical efficacy.

How do Inspira Technologies' solutions benefit healthcare providers?

By offering non-invasive respiratory support and continuous blood monitoring, the company’s technologies can improve patient care, reduce the complications associated with traditional ventilation, and provide rapid clinical information.

What distinguishes Inspira Technologies within the competitive medical device market?

The company combines breakthrough respiratory support technology with advanced, AI-powered blood monitoring, positioning it uniquely against traditional ventilation methods and addressing key clinical challenges.
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

17.00M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana